The federal government has embarked on a significant and controversial pilot program, leveraging artificial intelligence (AI) to inform insurance-coverage decisions, primarily within the Medicare system. This initiative seeks to address the long-standing challenges associated with prior authorization (PA) protocols, a bureaucratic hurdle that has plagued patients and healthcare providers for decades. However, while proponents herald AI as a potential panacea for efficiency, critics warn that its unchecked implementation could exacerbate existing inequities and lead to an increase in wrongful denials of medically necessary care.
The Persistent Burden of Prior Authorization
For countless Americans, the process of obtaining prior authorization for physician-recommended medical care is a labyrinthine ordeal fraught with delays and frustrations. Personal accounts frequently highlight the arduous journey patients undertake to secure approval from their health insurers for essential prescription medications, complex medical procedures, and specialized treatments. These narratives underscore the emotional and physical toll exacted by a system often perceived as designed to obstruct rather than facilitate care.
Physicians, too, are vocal about the administrative burden. A substantial majority of medical professionals express profound concerns regarding care delays directly attributable to prior authorization requirements. These delays can have severe consequences, including patients abandoning recommended treatments entirely while awaiting insurer verification of eligibility and medical necessity. When care is denied, patients are left to navigate a complex appeal process, which further consumes time and resources, often without immediate resolution. The 2026 Commonwealth Fund survey, for instance, revealed that nearly one in five working-age adults with private insurance reported experiencing a denial of coverage for physician-recommended care in 2025. Of those denied, a staggering 41 percent reported a delay in their care, and over a quarter observed a worsening of their health condition as a direct result.
Understanding Prior Authorization: Rationale and Controversy
Prior authorization, at its core, was conceived as a mechanism to control healthcare costs and prevent the overuse of services or technologies when less costly, equally effective alternatives exist. Insurers argue that it serves as a critical check against unnecessary spending, ensuring that treatments are appropriate and cost-effective. However, its implementation has frequently strayed from this ideal. What began as a tool for judicious oversight has, in many cases, transformed into a bottleneck that impedes timely access to care.
The administrative overhead associated with PA is immense. Healthcare providers dedicate significant staff time and resources—often hundreds of hours per year per physician—to managing PA requests, submitting documentation, and following up on approvals or denials. This burden diverts resources from direct patient care, contributing to physician burnout and increasing operational costs for clinics and hospitals, which are ultimately passed on to the healthcare system. The American Medical Association (AMA) has consistently voiced strong opposition to the current PA landscape, highlighting its detrimental impact on patient outcomes and the practice of medicine.
A Timeline of Reform Efforts
Recognizing the pervasive issues, various stakeholders have attempted to reform the prior authorization process over the years. These efforts have seen both legislative and industry-led initiatives aiming to alleviate the burden.
Biden Administration’s 2024 Rule: A notable stride towards reform came with a rule issued by the Biden administration in 2024. This regulation was specifically designed to reduce delays for patients enrolled in government-run plans, while simultaneously streamlining the PA process for physicians. Key provisions included mandatory response times for insurers: 72 hours for urgent requests and seven calendar days for non-urgent requests. These crucial timeline requirements officially came into effect on January 1 of the current year (2025) for most public sector health plans, marking a significant step towards standardizing and accelerating PA decisions.
Industry Pledges and Federal Pressure: In a parallel effort, the Trump administration, in collaboration with major insurers, pledged in 2024 to further streamline and accelerate prior authorization processes across the industry. This included commitments from private insurance companies to standardize electronic requests by 2027 and to reduce the overall volume of medical services subject to prior authorization by 2026. Specific common procedures like colonoscopies and cataract surgeries were cited as examples where PA requirements would be lessened, signaling an industry-wide acknowledgment of the problem. A senior CMS official, echoing federal sentiments, publicly warned insurance executives that without proactive measures to ease the PA burden, the federal government would impose stricter regulations, stating, "If you don’t do it yourselves, then we’re going to do it for you." This underscores the mounting pressure from policymakers on the private sector to improve efficiency and patient access.
The Dawn of AI in Medicare: The WISeR Model
Despite calls for easing prior authorization requirements in the private sector, federal health authorities under the Trump administration have simultaneously initiated a new program that expands the use of AI within original Medicare, a system where PA has historically been rare. This initiative, known as the Wasteful and Inappropriate Service Reduction (WISeR) Model, began its demonstration project this year.
Introduction to WISeR: The WISeR model is designed to leverage AI to identify and reduce waste and fraud in original Medicare, specifically targeting unnecessary procedures. Operating in six states through December 2031, the project integrates advanced technologies, including machine learning, with human clinical review. It focuses on evaluating services deemed vulnerable to overuse, fraud, and abuse, such as certain skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis. The Centers for Medicare and Medicaid Services (CMS) states that the WISeR model aims to "ensure timely and appropriate Medicare payment for select items and services" by integrating AI into the PA process.
The Shift to Original Medicare: The introduction of extensive prior authorization, particularly one driven by AI, into original Medicare represents a significant policy shift. Historically, beneficiaries in original Medicare have enjoyed broader access to services without the same level of pre-approval hurdles common in Medicare Advantage plans. This change has immediately raised red flags among patient advocates and healthcare reform proponents.
Concerns from Watchdogs and Advocates: Critics argue that rather than streamlining care, the WISeR model could replicate the problems seen in Medicare Advantage. A 2022 memorandum from the HHS Office of Inspector General (OIG) highlighted concerning patterns in Medicare Advantage, where plans denied beneficiaries access to services in more than one in ten instances, even when those services appeared to meet coverage rules. While a significant percentage of these denials (81% in 2024) were overturned upon appeal, the initial denial still created delays and stress for patients.
Wendell Potter, a prominent advocate for health insurance reform and a former Cigna executive, has extensively covered the political pushback against the WISeR model. Zena Wolf, a researcher with the Center for Health & Democracy, further elaborated on early findings from the model’s implementation. Investigations by leading news organizations such as The Washington Post, KFF Health News, and The Seattle Times suggest that within its initial months, the WISeR model has already led to care delays and denials in some of the six pilot states. Moreover, despite the promise of automation, healthcare providers have reported a continued high administrative burden, often involving additional work to address and appeal denials generated by the AI system.
Ethical Dilemmas and Financial Incentives
One of the most contentious aspects of the WISeR model is its financial structure. Vendors participating in the project, who are responsible for implementing the AI-driven prior authorization, are compensated with a share of what CMS terms "averted expenditures." This means that these vendors earn revenue for rejecting care requests, creating a direct financial incentive to deny services. This model reignites long-standing ethical concerns about profit-making based on discouraging patients from receiving medically necessary care.
The potential for conflicts of interest and the lack of transparency in AI algorithms are central to the debate. Lawmakers, including several members of Congress, have voiced strong objections, introducing resolutions and amendments aimed at blocking funding for the WISeR model. They cite the inherent threat to patient access when financial incentives are tied to denials, arguing that such a system risks prioritizing cost savings over patient well-being.
Conflicting Signals from Federal Health Leadership
The administration’s approach to prior authorization appears to be characterized by a paradoxical duality. On one hand, federal health authorities are actively expanding the use of AI in original Medicare through the WISeR model, effectively introducing a new layer of PA where it was previously minimal. On the other hand, the same administration is simultaneously exerting significant pressure on private insurers, including Medicare Advantage plans, to lessen and streamline their prior authorization processes. This seemingly contradictory stance highlights the complex and often competing priorities within healthcare policy: controlling costs in public programs versus ensuring patient access and reducing administrative burdens in the broader insurance market.
Industry’s Response and Transparency Commitments
In response to growing federal pressure and public outcry, health plans have recently released data suggesting compliance with administration demands to ease PA burdens. An industry-based survey, covering the period between June 2025 and April 2026, indicated an 11 percent reduction in requests for prior authorization. While this statistic suggests a positive trend in reducing the sheer volume of PA, it remains unclear whether the actual denial rate has decreased, leaving a critical question unanswered regarding true patient impact.
Furthermore, responding to an industry group survey conducted in 2025, all participating health plans affirmed that "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Insurers also pledged greater transparency regarding the clinical reasoning underpinning their prior authorization decisions. These commitments aim to alleviate concerns about fully automated denials and a lack of human oversight, though detractors remain skeptical about the practical implementation and effectiveness of these pledges.
The Road Ahead: Automation or Transformation?
The integration of AI into healthcare prior authorization stands at a critical juncture. While the technology holds undeniable potential to streamline administrative processes, reduce human error in routine approvals, and identify fraudulent claims, its deployment must be carefully managed to avoid exacerbating existing systemic flaws.
Jared Dashevsky, a physician and founder of Healthcare Huddle, a media and educational platform, articulated this tension eloquently. He acknowledged that AI "could eliminate barriers, reduce administrative waste, give us more time with patients. But that’s not what’s being built." Instead, he warns of an "arms race to deny faster and appeal faster," describing the current trajectory as "more automation of a broken system that shouldn’t exist in its current form."
The core challenge lies in distinguishing between automating an inefficient process and fundamentally transforming it for the better. True reform would require AI tools to be developed with an explicit mandate to facilitate appropriate care, not to serve as gatekeepers for cost savings at the expense of patient health. This necessitates robust oversight, mandatory transparency of algorithms, clear ethical guidelines, and ultimately, a re-evaluation of how financial incentives align with patient well-being.
As the WISeR model continues its pilot phase and private insurers navigate their pledges, the healthcare system watches closely. The ultimate success or failure of AI in prior authorization will hinge not merely on its technological capabilities, but on the commitment of policymakers, insurers, and providers to prioritize patient access and clinical necessity over purely economic considerations. The future of healthcare access for millions of Americans hangs in the balance.
